Original Article

Split Viewer

Blood Res 2020; 55(4):

Published online December 31, 2020

https://doi.org/10.5045/br.2020.2020174

© The Korean Society of Hematology

Radiotherapy for non-gastric intestinal versus gastric MALT lymphoma: a comparison of treatment outcomes

Shigenobu Watanabe1, Ichiro Ogino1, Masaharu Hata2

1Department of Radiation Oncology, Yokohama City University Medical Center, 2Department of Radiation Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Correspondence to : Shigenobu Watanabe, M.D., Ph.D.
Department of Radiation Oncology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
E-mail: kaninabe_30v@yahoo.co.jp

Received: July 16, 2020; Revised: September 7, 2020; Accepted: September 25, 2020

Abstract

Background
Radiotherapy is often used for treating patients with gastric mucosa-associated lymphoid tissue (MALT) lymphomas who fail to respond to Helicobacter pylori eradication. However, non-gastric intestinal MALT lymphoma is rare, and no standard therapeutic strategies have been established. This study was designed to assess the long-term prognosis of non-gastric intestinal MALT lymphoma treated with radiotherapy and to compare the outcomes with that of post-radiotherapy gastric MALT lymphoma.
Methods
The study included 34 patients with stage I EA gastrointestinal MALT lymphoma according to the Ann Arbor classification who underwent definitive radiotherapy. The primary site was the rectum in 3, the duodenum in 1, and the stomach in 30 patients. The radiotherapy dose was 1.5-2.0 Gy (median, 1.5 Gy) and the total dose was 30-40 Gy (median, 30 Gy). The clinical target volume (CTV) was defined as the volume of the entire organ with the lymphoma. Adjacent lymph node areas were not routinely included in the CTV.
Results
Complete response (CR) was achieved in all patients. There were no local recurrences, and two cases of recurrence were observed at other sites. The 5-year overall survival rates for non-gastric and gastric MALT lymphomas were 100% and 94.7%, respectively, and the 5-year disease-free survival rates were 100% and 95.7%, respectively. None of the patients died of the current illness.
Conclusion
Radiotherapy for non-gastric intestinal MALT lymphoma is expected to result in good local control and long-term survival, similar to that for gastric MALT lymphoma.

Keywords Non-gastric intestinal MALT lymphoma, Gastric MALT lymphoma, Radiotherapy, Survival, Local control

Article

Original Article

Blood Res 2020; 55(4): 200-205

Published online December 31, 2020 https://doi.org/10.5045/br.2020.2020174

Copyright © The Korean Society of Hematology.

Radiotherapy for non-gastric intestinal versus gastric MALT lymphoma: a comparison of treatment outcomes

Shigenobu Watanabe1, Ichiro Ogino1, Masaharu Hata2

1Department of Radiation Oncology, Yokohama City University Medical Center, 2Department of Radiation Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Correspondence to:Shigenobu Watanabe, M.D., Ph.D.
Department of Radiation Oncology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama 232-0024, Japan
E-mail: kaninabe_30v@yahoo.co.jp

Received: July 16, 2020; Revised: September 7, 2020; Accepted: September 25, 2020

Abstract

Background
Radiotherapy is often used for treating patients with gastric mucosa-associated lymphoid tissue (MALT) lymphomas who fail to respond to Helicobacter pylori eradication. However, non-gastric intestinal MALT lymphoma is rare, and no standard therapeutic strategies have been established. This study was designed to assess the long-term prognosis of non-gastric intestinal MALT lymphoma treated with radiotherapy and to compare the outcomes with that of post-radiotherapy gastric MALT lymphoma.
Methods
The study included 34 patients with stage I EA gastrointestinal MALT lymphoma according to the Ann Arbor classification who underwent definitive radiotherapy. The primary site was the rectum in 3, the duodenum in 1, and the stomach in 30 patients. The radiotherapy dose was 1.5-2.0 Gy (median, 1.5 Gy) and the total dose was 30-40 Gy (median, 30 Gy). The clinical target volume (CTV) was defined as the volume of the entire organ with the lymphoma. Adjacent lymph node areas were not routinely included in the CTV.
Results
Complete response (CR) was achieved in all patients. There were no local recurrences, and two cases of recurrence were observed at other sites. The 5-year overall survival rates for non-gastric and gastric MALT lymphomas were 100% and 94.7%, respectively, and the 5-year disease-free survival rates were 100% and 95.7%, respectively. None of the patients died of the current illness.
Conclusion
Radiotherapy for non-gastric intestinal MALT lymphoma is expected to result in good local control and long-term survival, similar to that for gastric MALT lymphoma.

Keywords: Non-gastric intestinal MALT lymphoma, Gastric MALT lymphoma, Radiotherapy, Survival, Local control

Fig 1.

Figure 1.The Kaplan–Meier curves for disease-free survival of the 4 non-gastric intestinal and 30 gastric MALT lymphoma patients.
Blood Research 2020; 55: 200-205https://doi.org/10.5045/br.2020.2020174

Fig 2.

Figure 2.The Kaplan–Meier curves for overall survival of the 4 non-gastric intestinal and 30 gastric MALT lymphoma patients.
Blood Research 2020; 55: 200-205https://doi.org/10.5045/br.2020.2020174

Table 1 . Patient characteristics..

Non-gastric MALT lymphoma, N=4 (%)Gastric MALT lymphoma, N=30 (%)
Sex
Male2 (50)14 (46.7)
Female2 (50)16 (53.3)
Age (yr)
Mean (range)71 (38–89)66 (31–82)
Abnormal uptake on FDG-PET
+3 (75)10 (33.3)
-1 (25)10 (33.3)
Not enforced0 (0)10 (33.3)
SUVmax
Mean (range)5.3 (3.7–17.1)6.0 (3.0–16.7)
H. pylori infection
+0 (0)14 (46.7)
-4 (100)16 (53.3)
Total treatment period (days)
Mean (range)28.5 (21–29)29 (26–35)
Prescription dose (Gy)
Mean (range)30 (30–30)30 (30–40)
Fractionation dose (Gy)
Mean (range)1.5 (1.5–2.0)1.5 (1.5–2.0)
Hemoglobin (g/dL)
Mean (range)11.3 (10.2–15.4)13.2 (9.3–16.3)
Platelet (×104/mL)
Mean (range)23.6 (20.8–26.3)23.0 (12.6–43.2)
Serum albumin (g/dL)
Mean (range)4.6 (3.7–5.5)4.5 (3.6–5.1)
Soluble IL2 receptor (U/mL)
Mean (range)433.4 (200–597.5)316.2 (200–713.5)
Immunoglobulin G (mg/dL)
Mean (range)1,333 (1,108–2,504)1,380 (847–2,138)
Immunoglobulin A (mg/dL)
Mean (range)310 (157–367)258 (107–396)
Immunoglobulin M (mg/dL)
Mean (range)84 (20–99)76 (38–275)
b2-microglobulin (mg/L)
Mean (range)1.87 (1.19–2.66)1.45 (1.04–4.32)

Abbreviations: FDG-PET, 18F-fluorodeoxy glucose-positron emission tomography; H. Pylori, Helicobacter pylori;IL2, interleukin 2; MALT, mucosa-associated lymphoid tissue; SUV, standardized uptake value..


Table 2 . Details of cases with recurrence..

No.Age/sexPrimary siteDose/fractionFractionTotal doseH. pylori infectionAdjuvant chemotherapyTreatment effectLocal recurrenceDistant recurrencePeriod until recurrence (mo.)Recurrence siteRecurrence PathologyOut comeObservation periodCause of death
165/FStomach1.52030+-CR-+67LungMALTAlive136-
272/MStomach1.52030--CR-+33Rectum and cecumDLBCLDead75Respiratory failure

Abbreviations: CR, complete response; F, female; H. pylori, Helicobacter pylori; M, male; MALT, mucosa-associated lymphoid tissue..


Blood Res
Volume 59 2024

Stats or Metrics

Share this article on

  • line

Related articles in BR

Blood Research

pISSN 2287-979X
eISSN 2288-0011
qr-code Download